INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB
INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB PR Newswire
LAB - Standard BioTools Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$3.25
DETAILS
HIGH:
$3.25
LOW:
$3.25
MEDIAN:
$3.25
CONSENSUS:
$3.25
UPSIDE:
348.09%
Stock News
Standard BioTools Reports Second Quarter 2026 Financial Results
BOSTON, Mass. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the "Company" or "Standard BioTools") today announced financial results for the quarter ended June 30, 2026. Recent Highlights: Second quarter 2026 revenue of $20.
Standard BioTools Reports Second Quarter 2026 Financial Results
BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026.
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close. About Standard BioTools Inc.
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Highlights combined company's strong financial position with over $900 million expected at closing, Treeline's deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program clinical starts
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)
BALA CYNWYD, Pa. , June 19, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.
LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers
SAN FRANCISCO--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced LiveRamp Agent Builders (LAB), a new program to bring more partner-built agents into its network and accelerate marketers' ability to transform planning, measurement, activation, and data transformation with AI. During LAB's pilot period, brands will have access to agents from all of the AI companies participating in the program, enabling customers to focus on finding tools that create value.
Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. Upon closing
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. Upon closing of the proposed transaction, Standard BioTools shareholders are expected to own approximately 16% of the combined company. Halper Sadeh encourages Standard BioTools shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 o.
Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Pacific Ridge Exploration Ltd. (TSXV: PEX) (OTCQB: PEXZF) (FSE: PQW) ("Pacific Ridge" or the "Company") is pleased to report that Labrador Gold Corp. (TSXV: LAB) ("LabGold") has announced plans for its 2026 exploration programs for the Company's Mariposa and Eureka Dome gold projects in the White Gold District, Yukon.
Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX Venture: LAB) ("Labrador Gold" or the "Company") is pleased to announce that it will host a live investor webinar on Wednesday, June 17, 2026, at 12:00 PM PT / 3:00 PM ET, featuring President and CEO Roger Moss and moderated by Cory Fleck of the KE Report. The webinar will provide investors with an in-depth overview of the Company's recently acquired Mariposa Gold Project, including its strategic location within the Yukon's prolific White Gold District, historical exploration results, the recently approved Class 1 permit, planned 2026 exploration activities and upcoming catalysts as the Company advances this district-scale gold opportunity.
Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript
Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript
Standard BioTools and Treeline Biosciences Announce Merger Agreement
Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
Standard BioTools (LAB) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
Standard BioTools Reports First Quarter 2026 Financial Results
BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026.
Reviewing Standard BioTools (NASDAQ:LAB) & Zhongchao (NASDAQ:ZCMD)
Standard BioTools (NASDAQ: LAB - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Insider and Institutional Ownership 53.7% of Standard BioTools